Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
100 a » 100 μ (Expand Search), 100 _ (Expand Search), 100 g (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
100 a » 100 μ (Expand Search), 100 _ (Expand Search), 100 g (Expand Search)
-
7301
-
7302
-
7303
-
7304
-
7305
-
7306
Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice
Published 2022“…Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …”
-
7307
Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice
Published 2022“…Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …”
-
7308
Synthesis and Biological Evaluation of Peripheral 5HT<sub>2B</sub> Antagonists for Liver Fibrosis
Published 2025“…<b>19c</b> markedly reduced fibrotic deposition, with a decrease in fibrosis stage and area in the CCl<sub>4</sub>-induced liver fibrosis mouse model. …”
-
7309
Synthesis and Biological Evaluation of Peripheral 5HT<sub>2B</sub> Antagonists for Liver Fibrosis
Published 2025“…<b>19c</b> markedly reduced fibrotic deposition, with a decrease in fibrosis stage and area in the CCl<sub>4</sub>-induced liver fibrosis mouse model. …”
-
7310
DataSheet_1_Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.docx
Published 2023“…</p>Results<p>Of 108 patients, 80 (74.1%) initiated low-dose RTX therapy immediately after acute attack treatment and 33 (30.6%) initiated it after the first attack. During a median treatment period of 35.5 (22.0–48.8) months, significant decreases were observed in median ARR (1.1 [0.8–2.0] versus 0 [0–0.2], p < 0.001), EDSS score (3.5 [2.5–4.0] versus 2.0 [1.0–3.0], p < 0.001) and spinal cord lesion segments (5.0 [4.0–8.0] versus 3.0 [1.0–6.0], p < 0.001). …”
-
7311
-
7312
-
7313
While <i>agr2</i><sup><i>+</i></sup> EMC numbers are not altered in <i>jag1a</i> mutants, <i>jag2b</i> mutants and <i>jag2b</i>-overexpressing embryos, Jagged1a, Jagged1b and Jagge...
Published 2021“…Scale bars, 100 μm. <b>(B).</b> Jag1a mutant protein is predicted to contain only MNNL, DSL and six EGF domains with a premature stop codon. …”
-
7314
-
7315
-
7316
-
7317
DataSheet_2_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.docx
Published 2024“…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
-
7318
DataSheet_1_IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia.xlsx
Published 2024“…A decrease in OS was found in IKZF1<sup>MUT</sup> and CDKN2A/2B<sup>MUT</sup> patients, but the significance was lost after IKZF1<sup>plus</sup> was removed.…”
-
7319
-
7320